Related Experiment Video
Updated: Mar 6, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
11.7K
Marginal zone lymphoma in elderly and geriatric patients
1Dept. I of Internal Medicine, University Hospital Cologne, Center of Integrated Oncology (CIO) Bonn-Cologne, Cologne, Germany; Division of Oncogeriatrics, Dept. of Geriatric Medicine, St. Marien-Hospital, Cologne, Germany.
Best Practice & Research. Clinical Haematology
|March 15, 2017
Summary
Older adults with marginal zone lymphoma (MZL) often have comorbidities. This review examines diagnostic and therapeutic challenges in geriatric MZL patients, suggesting geriatric assessments may be beneficial.
Area of Science:
- Hematology
- Geriatrics
- Oncology
Background:
- Marginal zone lymphoma (MZL) predominantly affects older adults, with a median age at diagnosis around 65-70 years.
- Limited research exists on comorbidities, polypharmacy, and geriatric syndromes in elderly MZL patients.
- The impact of these conditions on MZL treatment tolerance and feasibility remains under-investigated.
Purpose of the Study:
- To review current diagnostic and therapeutic guidelines for MZL.
- To identify potential barriers and complications in elderly and geriatric MZL patients.
- To explore the potential benefits of geriatric assessments in this population.
Main Methods:
- Literature review of diagnostic and therapeutic procedures for MZL.
- Extrapolation of findings from general cancer studies regarding geriatric patient management.
- Analysis of potential challenges in applying standard MZL protocols to older adults.
Main Results:
- Elderly MZL patients frequently present with advanced age and associated health issues.
- Standard diagnostic and therapeutic approaches may require modification for geriatric patients.
- Geriatric assessments could help mitigate risks and improve treatment outcomes.
Conclusions:
- Older adults with MZL face unique challenges due to age-related conditions.
- Tailoring diagnostic and therapeutic strategies, potentially incorporating geriatric assessments, is crucial for this demographic.
- Further research is needed to specifically address the needs of geriatric MZL patients.
Related Concept Videos
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
306
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
306
01:15Drug Dosing: Geriatric Patients
334
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
334
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
294
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
294
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
294
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
294
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
283
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
283
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
771
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
771